Part of the article also suggests that where efficacy is limited in vivo yet successful in vitro, it may be a delivery aspect that is needed, a method to enter the cells the currently doesnt exist under natural circumstances, a carrier, which allows collaborators to research if they have a vehicle that could get ATL-1102 inside the cells in vivo that dont naturally receive them. Which could, open up new areas of disease effect, and expanding the platform.
Reearch can just keep branching out in so many directions.
- Forums
- ASX - By Stock
- Some insights into backend work with ATL-1102
Part of the article also suggests that where efficacy is limited...
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
7.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $69.41M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 7.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.0¢ | 11000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 0.079 |
2 | 31331 | 0.078 |
1 | 48919 | 0.077 |
2 | 113467 | 0.075 |
1 | 200000 | 0.072 |
Price($) | Vol. | No. |
---|---|---|
0.080 | 11000 | 1 |
0.081 | 120000 | 1 |
0.083 | 206000 | 2 |
0.085 | 250000 | 2 |
0.087 | 25001 | 1 |
Last trade - 10.19am 06/05/2024 (20 minute delay) ? |
|
|||||
Last
7.9¢ |
  |
Change
0.000 ( 1.28 %) |
|||
Open | High | Low | Volume | ||
7.9¢ | 7.9¢ | 7.9¢ | 6979 | ||
Last updated 12.03pm 06/05/2024 ? |
Featured News
PER (ASX) Chart |
Day chart unavailable
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online